

Sadahisa Ogasawara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5525853/publications.pdf>

Version: 2024-02-01

136
papers

7,949
citations

172386

29
h-index

54882

84
g-index

140
all docs

140
docs citations

140
times ranked

7782
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816
2	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
3	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
4	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
5	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223.	4.2	307
6	Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. <i>Oncology</i> , 2014, 87, 22-31.	0.9	216
7	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 424-432.	3.7	216
8	Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. <i>Oncology</i> , 2014, 87, 330-341.	0.9	161
9	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. <i>Liver Cancer</i> , 2018, 7, 104-119.	4.2	95
10	Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 289-298.	2.3	87
11	Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 1257-1262.	1.2	75
12	Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. <i>Investigational New Drugs</i> , 2015, 33, 729-739.	1.2	75
13	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	4.2	71
14	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. <i>PLoS ONE</i> , 2014, 9, e84807.	1.1	70
15	Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e70010.	1.1	66
16	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <i>Hepatology</i> , 2018, 67, 575-585.	3.6	57
17	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. <i>Investigational New Drugs</i> , 2020, 38, 172-180.	1.2	57
18	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 382-396.	4.2	54

#	ARTICLE	IF	CITATIONS
19	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52
20	Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. <i>BMC Cancer</i> , 2019, 19, 795.	1.1	48
21	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 155-162.	4.5	44
22	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 354-367.	4.2	44
23	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 2011, 5, 850-856.	1.9	40
24	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. <i>Investigational New Drugs</i> , 2016, 34, 255-260.	1.2	40
25	Current management of patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1913.	0.8	40
26	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 21315-21326.	0.8	39
27	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204.	1.4	36
28	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
29	Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. <i>Magnetic Resonance Imaging</i> , 2013, 31, 748-754.	1.0	34
30	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>PLoS ONE</i> , 2015, 10, e0125244.	1.1	34
31	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
32	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 906.	1.8	28
33	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 1088.	1.1	28
34	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 473-484.	4.2	28
35	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
36	Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. <i>PLoS ONE</i> , 2018, 13, e0209352.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. <i>Hepatology International</i> , 2018, 12, 523-530.	1.9	24
38	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 707-712.	1.1	21
39	Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2014, 34, 4231-7.	0.5	21
40	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. <i>Liver Cancer</i> , 2019, 8, 505-519.	4.2	20
41	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	2.0	20
42	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	1.6	20
43	Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2014, 39, 262-268.	2.0	19
44	Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 238-245.	0.3	18
45	EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 21396.	1.6	17
46	Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. <i>Journal of Gastroenterology</i> , 2018, 53, 652-659.	2.3	16
47	Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 908-915.	1.4	15
48	Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170153.	1.1	15
49	Changes in therapeutic options for hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2055-2066.	1.9	14
50	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 549, 171-178.	1.0	13
51	Clinical outcomes of endoscopic ultrasound-guided ethanol injection for hepatocellular carcinoma in the caudate lobe. <i>Endoscopy International Open</i> , 2016, 04, E1111-E1115.	0.9	12
52	Biological features and biomarkers in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2020.	0.8	12
53	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 723-728.	1.2	11
54	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. <i>International Journal of Medical Sciences</i> , 2016, 13, 310-315.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Successful Interventional Treatment for Arterioportal Fistula Caused by Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2014, 7, 833-839.	0.3	10
56	Intensity-Based Assessment of Microbubble-Enhanced Ultrasonography: Phase-Related Diagnostic Ability for Cellular Differentiation of Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3079-3087.	0.7	10
57	Incidence and hemodynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. <i>International Journal of Medical Sciences</i> , 2019, 16, 1614-1620.	1.1	10
58	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
59	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 268-268.	0.8	10
60	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. <i>Oncotarget</i> , 2018, 9, 11631-11637.	0.8	10
61	Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. <i>Cancers</i> , 2021, 13, 2626.	1.7	9
62	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. <i>JGH Open</i> , 2021, 5, 1266-1274.	0.7	9
63	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2021, 12, 2694-2701.	1.2	8
64	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	1.7	8
65	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 703-713.	1.9	7
66	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161303.	1.1	7
67	Hepatic Sarcoidosis with an Increased Serum Level of Immunoglobulin G4. <i>Internal Medicine</i> , 2012, 51, 3095-3098.	0.3	6
68	Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan. <i>Hepatology International</i> , 2013, 7, 1030-1039.	1.9	6
69	Successful Non-surgical Treatment of Ruptured Pyogenic Liver Abscess. <i>Internal Medicine</i> , 2013, 52, 2619-2622.	0.3	6
70	Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1403-1411.	0.6	6
71	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0163119.	1.1	6
72	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. <i>Journal of Gastroenterology</i> , 2022, 57, 90-98.	2.3	6
74	Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2015, 35, 549-54.	0.5	6
75	Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical Experience. <i>Journal of Cancer</i> , 2022, 13, 2656-2661.	1.2	6
76	A phase I/II trial of capecitabine combined with peginterferon α -2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 762-768.	1.2	5
77	Intracranial Metastasis in a Patient with Hepatocellular Carcinoma and Gastric Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 199-203.	0.3	5
78	Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. <i>Stem Cells International</i> , 2019, 2019, 1-10.	1.2	5
79	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. <i>International Journal of Medical Sciences</i> , 2020, 17, 874-880.	1.1	5
80	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. <i>Oncotarget</i> , 2018, 9, 16263-16270.	0.8	5
81	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340.	4.2	5
82	Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	4
83	Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?. <i>International Journal of Clinical Oncology</i> , 2014, 19, 1029-1036.	1.0	4
84	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 297-297.	0.8	4
85	Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 273-279.	0.7	4
86	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0261619.	1.1	4
87	A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. <i>Laboratory Investigation</i> , 2022, 102, 1150-1157.	1.7	4
88	Successful Resection of Intracranial Metastasis of Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2013, 7, 182-187.	0.3	3
89	Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E161-2.	1.8	3
90	Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2017, 56, 3041-3045.	0.3	3

#	ARTICLE	IF	CITATIONS
91	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 323-323.	0.8	3
92	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. <i>World Journal of Gastroenterology</i> , 2015, 21, 8888.	1.4	3
93	Dexamethasone for the prevention of transcatheter arterial chemoembolization-induced fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma: A randomized, double-blind, placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4071-4071.	0.8	3
94	Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2013, 33, 5603-9.	0.5	3
95	Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 41-46.	0.4	2
96	A case of hepatocellular carcinoma with spontaneous regression of a tumor thrombus invading the main portal trunk. <i>Acta Hepatologica Japonica</i> , 2016, 57, 178-185.	0.0	2
97	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. <i>Acta Hepatologica Japonica</i> , 2017, 58, 647-653.	0.0	2
98	REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4162-TPS4162.	0.8	2
99	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4072-4072.	0.8	2
100	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	0.8	2
101	Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS595-TPS595.	0.8	2
102	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS494-TPS494.	0.8	2
103	Simultaneous Resection of Disseminated Hepatocellular Carcinoma and Colon Cancer. <i>Case Reports in Gastroenterology</i> , 2013, 7, 37-43.	0.3	1
104	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. <i>Acta Hepatologica Japonica</i> , 2015, 56, 469-476.	0.0	1
105	Two patients with hepatic mucosa-associated lymphoid tissue lymphoma resembling hypervascular hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 536-539.	0.0	1
106	Successful treatment of three elderly patients aged 80-90 years with hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 628-631.	0.0	1
107	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. <i>Acta Hepatologica Japonica</i> , 2016, 57, 557-560.	0.0	1
108	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2017, 58, 605-610.	0.0	1

#	ARTICLE	IF	CITATIONS
109	Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. <i>International Journal of Medical Sciences</i> , 2017, 14, 804-810.	1.1	1
110	PS-142-Analysis of sorafenib-regorafenib sequential therapy in patients with advanced hepatocellular carcinoma using baseline date of sorafenib. <i>Journal of Hepatology</i> , 2019, 70, e90-e91.	1.8	1
111	Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 253-254.	0.7	1
112	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. <i>Acta Hepatologica Japonica</i> , 2021, 62, 25-32.	0.0	1
113	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4074-4074.	0.8	1
114	Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2021, 14, 1103-1110.	0.3	1
115	Diagnostic value of peroral cholangioscopy in addition to computed tomography for indeterminate biliary strictures. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, , 1.	1.3	1
116	Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 278-278.	0.8	1
117	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2020, 38, 528-528.	0.8	1
118	Serum creatinine/cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S400.	1.8	1
119	Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 467-467.	0.8	1
120	Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS495-TPS495.	0.8	1
121	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. <i>BMJ Open</i> , 2022, 12, e059779.	0.8	1
122	Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis. <i>Annals of Hepatology</i> , 2022, 27, 100696.	0.6	1
123	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	1
124	Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine. <i>Acta Hepatologica Japonica</i> , 2015, 56, 213-216.	0.0	0
125	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35.	0.3	0
126	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. <i>Acta Hepatologica Japonica</i> , 2017, 58, 176-182.	0.0	0

#	ARTICLE	IF	CITATIONS
127	Hepatocellular carcinoma after direct-acting antiviral agents: Can liver stiffness kinetics help identify patients at lower risk?. <i>Digestive and Liver Disease</i> , 2018, 50, 580-582.	0.4	0
128	FRI-501-Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras. <i>Journal of Hepatology</i> , 2019, 70, e620.	1.8	0
129	FRI-490-The real world practice of systemic therapies in patients with advanced hepatocellular carcinoma in Japan: what has changed since lenvatinib approval?. <i>Journal of Hepatology</i> , 2019, 70, e614-e615.	1.8	0
130	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 318-318.	0.8	0
131	Approaching the tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples.. <i>Journal of Clinical Oncology</i> , 2021, 39, 334-334.	0.8	0
132	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16122-e16122.	0.8	0
133	A case of Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 548-554.	0.0	0
134	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 656-662.	0.0	0
135	A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 346-346.	0.8	0
136	Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 468-468.	0.8	0